NASDAQ$SNDX
Syndax Pharmaceuticals Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Syndax reported third quarter 2023 financial results and provided a clinical and business update.
Syndax Pharmaceuticals reported its financial results for the quarter ended September 30, 2023. The company continues to advance its pipeline, with NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia and plans to submit a BLA filing for axatilimab by year-end 2023.
- NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR.
- Final Phase 1 mNPM1 data from AUGMENT-101 demonstrates a 36% CR/CRh rate.
- Revumenib and axatilimab U.S. registrational filings are on track for year-end 2023 completion and potential 2024 approvals.
- Axatilimab to be featured in plenary session at 65th ASH Annual Meeting.
Headline financials
Revenue & EPS history
Syndax · Revenue · Quarterly
$0
Forward guidance
Syndax provided financial guidance for the full year of 2023.
Tailwinds
- Research and development expenses are expected to be $160 to $165 million.
- Total operating expenses are expected to be $225 to $230 million.
- Guidance reflects a reduction from prior expectations.
- Company expects to complete the NDA submission for revumenib by year-end 2023.
- Company and Incyte expect to submit a Biologics License Application (BLA) filing for axatilimab by year-end 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+1.6%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+3.5%
Avg return
30 days after
60%
24 / 40 earnings
Positive
+15.1%
Q4 2019
Best reaction
-21.6%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -2.6% | -5.2% | |
| Q4 2025 | +5.1% | +4.6% | +13.6% | |
| Q3 2025 | +11.6% | +9.3% | +43.5% | |
| Q1 2025 | -21.6% | -21.1% | -17.8% | |
| Q4 2024 | -7.1% | -13.3% | -19.5% | |
| Q3 2024 | +12.7% | +15.2% | -11.3% | |
| Q2 2024 | -7.3% | -12.3% | -9.5% | |
| Q1 2024 | -5.2% | -9.5% | -15.9% | |
| Q4 2023 | -2.1% | -2.7% | -2.4% | |
| Q3 2023 | +6.3% | +5.0% | +19.0% | |
| Q2 2023 | -3.5% | -10.9% | -4.5% | |
| Q1 2023 | +7.8% | +5.0% | +3.8% | |
| Q4 2022 | +1.6% | -0.1% | -15.6% | |
| Q3 2022 | -2.0% | -2.2% | +9.5% | |
| Q2 2022 | +0.5% | +0.5% | -2.4% | |
| Q1 2022 | -5.8% | -12.3% | +10.1% | |
| Q4 2021 | +3.3% | -2.2% | +11.5% | |
| Q3 2021 | +2.1% | -0.9% | +5.9% | |
| Q2 2021 | +7.0% | +11.2% | +23.9% | |
| Q1 2021 | +14.6% | +18.5% | +21.5% | |
| Q4 2020 | +0.4% | -2.8% | -5.3% | |
| Q3 2020 | +8.8% | +20.4% | +30.9% | |
| Q2 2020 | +6.5% | -0.9% | +0.7% | |
| Q1 2020 | -1.8% | +3.2% | -8.0% | |
| Q4 2019 | +15.1% | +22.8% | -0.6% | |
| Q3 2019 | -0.3% | +0.3% | +24.5% | |
| Q2 2019 | +10.6% | +8.6% | -3.0% | |
| Q1 2019 | +9.1% | +6.1% | +3.9% | |
| Q4 2018 | -13.5% | -11.1% | -4.2% | |
| Q3 2018 | +2.1% | +5.9% | -3.5% | |
| Q2 2018 | +12.0% | +6.7% | +8.8% | |
| Q1 2018 | +9.9% | +1.5% | -25.5% | |
| Q4 2017 | -1.5% | -0.6% | +47.9% | |
| Q3 2017 | -11.7% | -10.1% | -28.4% | |
| Q2 2017 | -5.7% | -1.5% | +8.0% | |
| Q1 2017 | -7.0% | +4.7% | +26.7% | |
| Q4 2016 | +5.0% | +1.0% | +18.0% | |
| Q3 2016 | +0.9% | -4.9% | -17.1% | |
| Q2 2016 | +5.6% | +5.5% | +3.1% | |
| Q1 2016 | -2.1% | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro